

Role of advanced MRI techniques in predicting and evaluating the response of breast cancer to neoadjuvant chemotherapy

Essay

**Submitted for partial fulfillment of master
degree in Radiodiagnosis**

by

Mouna Abdulaziz A elkhoja

M.B.B. Ch. – faculty of Medicine , Tripoli University

Under supervision of

Prof. Dr. Dalia Zaki Zidan

Professor of Radiodiagnosis

Faculty of Medicine, Ain Shams University

Dr. Nermeen Nasry Halim

Lecturer of Radiodiagnosis

Faculty of Medicine, Ain Shams University

Faculty of Medicine

Ain Shams University

2016

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قُلْ إِنْ صَلَاتِي

وَنَسْكَي

وَمَحْيَايَ وَمَمَاتِي

لِلَّهِ رَبِّ الْعَالَمِينَ

صِرَاطَ اللَّهِ الْعَظِيمِ

سورة الأنعام الآية (١٦٢)



First thanks to **ALLAH** to whom I relate any success in achieving any work in my life.

I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Dalia Zaki Zidan**, Professor of Radiodiagnosis Faculty of Medicine Ain Shams University, for his meticulous supervision, kind guidance, Valuable instructions and generous help.

Special thanks are due **Dr. Nermeen Nasry Halim**, Lecturer of Radiodiagnosis Faculty of Medicine Ain Shams University for her sincere efforts and fruitful encouragement.

Also I would like to thank my **Family** and who stood behind me to finish this work and for their great support.

✍ *Mouna Abdulaziz Alkhoja*

List of Contents

<i>Title</i>	<i>Page No.</i>
List of Contents.....	<i>i</i>
List of Tables.....	<i>ii</i>
List of Figures	<i>iii</i>
Introduction.....	- 1 -
Aim of work.....	- 4 -
<i>Review of Literature</i>	
Anatomy of the breast and mri appearance	- 5 -
PATHOLOGY of breast cancer	- 16 -
Principles of Mri of the Breast	- 34 -
Interpretation of Mri Breast Lesions.....	- 40 -
Role Of Advanced MRI techniques in prediction and evaluation of neoadjuvant chemotherapy Effect on breast cancer.....	- 70 -
Summary	- 115 -
References.....	- 118 -
Arabic summary	--

List of Tables

<i>Table No.</i>	<i>Title</i>	<i>Page No.</i>
Table (1):	Histologic classification of breast cancer	- 19 -
Table (2):	TNM Stage Grouping for Breast Cancer.	- 32 -
Table (3):	is an example of an MRI breast imaging protocol performed at the Memorial Sloan-Kettering Cancer Center.	- 37 -
Table (4):	Breast MRI Terms Proposed by the International Working Group of the American College of Radiology	- 43 -
Table (5):	Change of enhanced parameters of 44 lesions during NAC.....	- 79 -

List of Figures

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (1):	Schematic of sagittal views of the breast.	5 -
Figure (2):	Nipples on MRI may (A) enhance intensely, (B) mildly, or (C) not at all, depending on blood supply	6 -
Figure (3):	Medial breast with pectoralis major muscle (arrow) overlying ribs (curved arrow) and intercostal muscles (thick arrow).....	7 -
Figure (4):	Laterally in the breast the pectoralis minor is visualized (arrow) behind the pectoralis major muscle..	7 -
Figure (5):	Pectoralis major muscle (arrow) and pectoralis minor muscle (curved arrow). Axillary artery identified (thick arrow).....	8 -
Figure (6):	Glandular breast tissue	9 -
Figure (7):	Blood supply of the breast.....	10 -
Figure (8):	Lateral thoracic artery (arrow) and branches	10 -
Figure (9):	Internal mammary artery (arrow) anterior to the heart....	11 -
Figure (10):	Lymphatic drainage of the breast	13 -
Figure (11):	Multiple normal appearing level I axillary lymph nodes posterior to pectoralis major muscle	13 -
Figure (12):	Lymph node in the posterior medial breast. Presence of vessel extending to hilum and characteristic reniform appearance allows diagnosis	14 -
Figure (13):	Benign lymph node with vessel radiating to hilum....	14 -
Figure (14):	Nerve supply of the breast.....	15 -
Figure (15):	Intraductal carcinoma, comedo type. Distended duct with intact basement membrane and central tumor necrosis.....	20 -
Figure (16):	Well-differentiated ductal carcinoma in situ with a cribriform pattern of growth.....	20 -
Figure (17):	Lobular intraepithelial neoplasia	22 -
Figure (18):	Invasive ductal carcinoma	24 -
Figure (19):	Invasive lobular carcinoma	25 -
Figure (20):	Mucinous carcinoma, hypocellular variant	26 -

List of Figures (Cont.)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (21):	T1 is further divided into 4 groups	30 -
Figure (22):	T2 – The tumour is more than 2 centimetres, but no more than 5 centimetres across. (2-5 cm)	30 -
Figure (23):	T3 – The tumour is bigger than 5 centimetres across..	31 -
Figure (24):	(a– d) The same section is displayed throughout the dynamic series, from 69 seconds after injection (a) through the fourth scan obtained 4 minutes 36 seconds after injection (d). Note that contrast between cancer (arrow) and normal fibroglandular tissue (arrowheads) on both sides is best on a, very early in postcontrast phase. Owing to strong washout effect of the cancer and progressive signal intensity increase of normal parenchyma, the cancer may even be overlooked on d.	38 -
Figure (25):	A postcontrast sagittal image demonstrates a multilobulated IDC in the lower posterior region of the breast	39 -
Figure (26):	Algorithm for interpretation	42 -
Figure (27):	Multiple foci of enhancement (arrows) throughout right breast. All foci were stable for at least 1.5 years and were considered benign	44 -
Figure (28):	Mass shape may be defined as round, oval, lobulated, or irregular.	45 -
Figure (29):	The image on the left is a juvenile fibroadenoma - it is oval in shape and has smooth margins, i.e. typically benign. The non-enhancing septations are not seen in this case.	45 -
Figure (30):	Lobulated mass lesion-Lobular invasive carcinoma ...	46 -
Figure (31):	Large, round mass with smooth margins, which turned out to be an epidermal inclusion cyst.....	46 -
Figure (32):	Oval smooth lymph node	47 -
Figure (33)	Small round smooth carcinoma	47 -

List of Figures *(Cont.)*

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (34)	Sagittal 3D FSPGR image with fat suppression shows malignant mass with spiculated margins.....	- 47 -
Figure (35):	Fat-containing hamartoma with high signal on T1WI (arrow).....	- 48 -
Figure (36):	Two examples of a hamartoma with dark areas of fat on a fat suppressed T1WI with Gd.....	- 48 -
Figure (37):	Examples of cysts.....	- 49 -
Figure (38):	Fibroadenoma (left) and a colloid carcinoma (right). Both are bright on T2WI.	- 49 -
Figure (39):	Homogeneous enhancement.....	- 51 -
Figure (40):	Invasive lobular carcinoma with heterogenous enhancement.....	- 51 -
Figure (41):	Invasive ductal carcinoma with rim enhancement invading the surrounding tissue	- 52 -
Figure (42):	Inflammatory cysts	- 52 -
Figure (43):	Fat necrosis following surgery	- 52 -
Figure (44):	Phylloides tumour	- 53 -
Figure (45):	Enhancing internal septations.....	- 53 -
Figure (46):	Central enhanced nidus (arrows) and enhanced internal septum (arrowhead). Pathologic assessment revealed invasive high-grade ductal carcinoma.	- 54 -
Figure (47):	Kinetic curve assessment.	- 55 -
Figure (48):	The CAD shows a large area of red superimposed on the breast lesion .In CAD, red is bad: it means type 3 washout, and probably cancer	- 58 -
Figure (49):	A large, abnormally enhancing area in the left breast. The CAD has detected some very small areas with type 3 washout (in red). This was a large invasive ductal carcinoma.	- 58 -
Figure (50):	Focal DCIS	- 60 -
Figure (51):	Ductal enhancement in DCIS	- 60 -

List of Figures (Cont.)

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (52):	A mass as well as areas of linear non-mass enhancement (ductal) This proved to be linear DCIS with an invasive ductal carcinoma.	60 -
Figure (53):	Linear enhancement in scars following surgery	61 -
Figure (54):	MIP demonstrating linear enhancement in scar (arrow).....	61 -
Figure (55):	Segmental enhancement	61 -
Figure (56):	Regional enhancement in a case of DCIS.	62 -
Figure (57):	Diffuse enhancement (A) Initial study in the third week of the menstrual cycle in a premenopausal woman. (B) Follow up several months later in the second week of the cycle demonstrates much less parenchymal enhancement.	62 -
Figure (58):	Punctate enhancement in a hamartoma with fibrocystic change (arrows).....	63 -
Figure (59):	Nonmasslike enhancements	64 -
Figure (60):	Nipple invasion.Subareolar invasive ductal carcinoma	65 -
Figure (61):	Diffuse skin thickening with enhancement. Inflammatory breast carcinoma. Note reticular dendritic pattern of enhancement in the breast.	66 -
Figure (62):	Locally advanced breast carcinoma with axillary adenopathy	66 -
Figure (63):	Hematoma: Image demonstrates high signal intensity of postoperative hematoma following surgery with thin rim of enhancement around hematoma cavity representing immediate postoperative changes.....	67 -
Figure (64):	Abnormal signal void from a metallic clip placed during stereotactic biopsy. Note residual clumped enhancement around the clip indicating residual DCIS.....	67 -

List of Figures *(Cont.)*

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (65):	Chest wall invasion. Note dominant carcinoma in lower breast. Posterior satellite lesion invades intercostal muscle.....	- 68 -
Figure (66):	A 58-year-old woman with locally advanced breast carcinoma had MRI prior to chemotherapy. Note that the retroareolar mass invades the nipple and surrounding skin. Extensive involvement of the breast is also noted. On physical examination, she had thickened skin anteriorly with peau d'orange	- 69 -
Figure (67):	A 43-year-old woman demonstrates extensive areas of abnormal enhancement suspicious for locally advanced breast carcinoma.	- 69 -
Figure (68):	Signal intensity-time curve.....	- 73 -
Figure (69):	Pixel-by-pixel colour maps with each pixel representing values for K trans.	- 76 -
Figure (70):	Images obtained from a 64-year-old Woman with Invasive Ductal Carcinoma Who Obtained Pathologic Complete Response after Chemotherapy.....	- 81 -
Figure (71):	Images Obtained From a 45-Year-Old Woman With Invasive Ductal Carcinoma Who Was Included in Non-Pathologic Complete Response Group.....	- 82 -
Figure (72):	Change of SI-Time curve before and after 1st cycle of NAC in responders.....	- 84 -
Figure (73):	Change of SI-Time curve before and after 1st cycle of NAC in non-responders	- 84 -
Figure (74):	MRI scan picture of breast cancer (arrow).....	- 86 -
Figure (75):	MRI scan picture of breast cancer (arrow).....	- 87 -
Figure (76):	Single voxel spectra from healthy breast tissue	- 92 -
Figure (77):	Different pathological tissue types have different MRS characteristics	- 92 -
Figure (78):	Example of a localized breast spectrum acquired at 4 T.	- 94 -

List of Figures *(Cont.)*

<i>Fig. No.</i>	<i>Title</i>	<i>Page No.</i>
Figure (79):	Mammographically detected, biopsy-proved invasive ductal carcinoma (true positive finding) of the left breast in a 52-year-old woman.....	- 95 -
Figure (80):	Dynamic magnetic resonance imaging (MRI) and proton magnetic resonance spectroscopy (1H-MRS) of the breast.	- 95 -
Figure (81):	verage spectra (spectral regions; 2.90-3.65 and 3.75-4.7ppm) of samples from patients with a) PR (n=11 pre/11 post) and b) SD (n=19 pre/14 post), pre- (left) and post- (right) treatment.....	- 100 -
Figure (82):	Monitoring of Neoadjuvant Chemotherapy by MR Spectroscopy	- 101 -
Figure (83):	Maximum intensity projection MR images (left) and corresponding MR spectra (right) from 40-year-old patient who achieved pCR.(A) Before treatment, 3.4-cm lesion (arrow) shows heterogeneous enhancing pattern.....	- 102 -
Figure (84):	Maximum intensity projection MR images of 29-year-old woman (patient 24) who had residualinvasive cancer after completing NAC.....	- 103 -
Figure (85):	ADC map. Note the posterior cyst with hyperintense signal (open arrow) and an anterior breast carcinoma with low signal (solid arrow) (Brandao et al., 2013) .	- 105 -
Figure (86):	Breast cancer on DWI &Corresponding ADC map, appearing as a dark signal	- 107 -
Figure (87):	DWI interpretation strategies.	- 108 -
Figure (88):	Graph illustrates the correlation between $\exp(-b \cdot D)$ and b value at various diffusion coefficients.....	- 109 -
Figure (89):	Ductal carcinoma in situ (DCIS) in the left breast. ...	- 111 -

Introduction

Worldwide, breast cancer is the most frequently diagnosed life-threatening cancer in women and the leading cause of cancer death among women (*Swart, 2010*).

In Egypt, breast cancer is the most common cancer among women, representing 18.9% of total cancer cases (35.1% in women and 2.2% in men)(*Omar et al., 2003*).

Although its incidence continues to rise, mortality has declined over the past several years. The decline has been attributed to both early diagnosis and more effective treatment (*Jean et al., 2009*).

Diagnostic imaging can make the largest contributions towards improving the management and outcome of women with breast cancer by new effective methods of following therapy and establishing prognosis (*Powe 1997, Hoh et al., 1993*).

This is especially important in locally advanced breast cancer which remains a challenging clinical problem (*Whitman and Strom, 2009*).

Neoadjuvant chemotherapy (NAC) followed by surgery was introduced about 2 decades ago to treat patients with locally advanced breast cancer, which represents approximately 20% of all women who receive a diagnosis of breast cancer (*Jean-Paul et al., 2003*).

While neoadjuvant chemotherapy achieves the same survival rates as postoperative chemotherapy in women with operable breast carcinoma, the advantages of neoadjuvant treatment over conventional adjuvant chemotherapy are manifold (*Rosen et al., 2003 Yeh et al., 2005*).

First, and most importantly, chemotherapy given before surgery may shrink the large tumors to improve the resectability in some (inoperable to operable) and to allow for breast conservation surgery in others (fewer mastectomies) (*Rosen et al., 2003 Yeh et al., 2005*).

Second, it allows for assessment of tumor response in each patient (*Rosen et al., 2003 Yeh et al., 2005*).

NAC gives high clinical response rates (70-98%) and can even achieve pathological complete response (PCR) in a subgroup of patients (3-34%). The prediction of PCR from the early response can contribute to a timely adjustment of treatment protocol to help reach this goal, and to avoid unnecessary toxicity of ineffective treatments. While on the other hand it permits early detection of resistant tumors to choose alternative and possibly more efficacious treatments, such as other types of chemotherapy or early surgery (*Mei-Lin et al., 2008 Hyeon-Man et al., 2009*).

Third, the upfront nature of this treatment provides the earliest chance to treat micro-metastatic disease and saves time, unlike conventional adjuvant chemotherapy that may be delayed for several months because of surgical scheduling and the need for wound healing (*Rosen et al., 2003 Yeh et al., 2005*).

Lastly, the intact neo-vasculature can be exploited to the advantage of the patient. Because surgical excision may alter the tumor's vasculature, neoadjuvant chemotherapy may have the advantage of enhancing the local effect through a non-disturbed blood supply (*Rosen et al., 2003, Yeh et al., 2005*).

Following neoadjuvant chemotherapy, accurate assessment of early tumor response or size of post therapy residual tumor burden and location is necessary for planning

the future medical or surgical roadmap of the patient. Monitoring of response has traditionally been based on physical examination, mammography, and sonography of the breast. However, these techniques were found to result in unsatisfactory accuracy due to the development of chemotherapy-induced fibrosis (*Loo et al., 2008*).

Advanced MRI imaging techniques as Magnetic resonance spectroscopy (MRS) - Pharmacokinetic assessment in DCE (MRI) - Diffusion weighted imaging (DWI) have shown to be of great importance in monitoring patient's response to chemotherapy, and in differentiating responders from non-responders early during therapy (*Rosen et al. 2003 Pickles et al., 2005*).

They also play an important role in assessment of tumor extent after the end of the cycles of chemotherapy (*Balu-Maestro et al., 2002*).

Aim of work

The purpose of this study is to evaluate the diagnostic ability of advanced MRI imaging techniques in predicting the effect of neoadjuvant chemotherapy on breast cancer early in the treatment regimen and evaluating its effect during and after the course.